Literature DB >> 17409998

Surgery for bronchioloalveolar carcinoma and "very early" adenocarcinoma: an evolving standard of care?

Valerie W Rusch1, Ryosuke Tsuchiya, Masahiro Tsuboi, Harvey I Pass, Dominique Grunenwald, Peter Goldstraw.   

Abstract

Lobectomy and mediastinal lymph node dissection is the standard surgical management of early stage non-small cell lung cancer (NSCLC) because more limited resections have been associated with a higher risk of local recurrence. Nevertheless, recent lung cancer screening studies have led to the detection of an increasing number of "very early" NSCLC (defined as less than 2 cm in size) and of good-prognosis histologic subtypes, bronchioloalveolar carcinoma (BAC), and adenocarcinoma (AC), mixed subtypes that are potentially appropriate for sublobar resection. The precise indications for sublobar resection remain unclear and are the subject of ongoing clinical trials, but it seems that very early, peripherally located, node-negative AC of a predominantly BAC pattern may be adequately treated in this manner. Multifocal AC and BAC, either synchronous or metachronous, are also effectively treated by complete resection, using limited resections whenever possible. The pneumonic form of BAC, the rarest variant of this disease spectrum, continues to have a poor prognosis despite complete resection. Very limited experience suggests that lung transplantation leads to prolonged survival in highly selected patients with this histologic subtype. To improve our management of very early AC, much more information is needed about the molecular abnormalities of AC and their relationship to clinical outcomes.

Entities:  

Mesh:

Year:  2006        PMID: 17409998

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  6 in total

1.  Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504).

Authors:  Suresh S Ramalingam; Ju-Whei Lee; Chandra P Belani; Seena C Aisner; Jill Kolesar; Craig Howe; Mario R Velasco; Joan H Schiller
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

2.  Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies.

Authors:  Mark L Kayton; Mai He; Maureen F Zakowski; Andre L Moreira; Christopher Lau; Alexander J Chou; Melinda Merchant; Pamela R Merola; Leonard H Wexler; Michael P La Quaglia; William D Travis; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2010-11       Impact factor: 15.609

3.  Outcomes: wedge resection versus lobectomy for non-small cell lung cancer at the Cancer Centre of Southeastern Ontario 1998-2009.

Authors:  Anna L McGuire; Wilma M Hopman; Dimitri Petsikas; Ken Reid
Journal:  Can J Surg       Date:  2013-12       Impact factor: 2.089

4.  The Outcomes of a Limited Resection for Non-Small Cell Lung Cancer Based on Differences in Pathology.

Authors:  Motoki Yano; Junji Yoshida; Terumoto Koike; Kotaro Kameyama; Akira Shimamoto; Wataru Nishio; Kentaro Yoshimoto; Tomoki Utsumi; Takayuki Shiina; Atsushi Watanabe; Yasushi Yamato; Takehiro Watanabe; Yusuke Takahashi; Makoto Sonobe; Hiroaki Kuroda; Makoto Oda; Masayoshi Inoue; Masayuki Tanahashi; Hirofumi Adachi; Masao Saito; Masataro Hayashi; Hajime Otsuka; Teruaki Mizobuchi; Yasumitsu Moriya; Mamoru Takahashi; Shigeto Nishikawa; Yuki Matsumura; Satoru Moriyama; Yoshitaka Fujii
Journal:  World J Surg       Date:  2016-11       Impact factor: 3.352

5.  Limited Resection Versus Lobectomy for Older Patients With Early-Stage Lung Cancer: Impact of Histology.

Authors:  Rajwanth R Veluswamy; Nicole Ezer; Grace Mhango; Emily Goodman; Marcelo Bonomi; Alfred I Neugut; Scott Swanson; Charles A Powell; Mary B Beasley; Juan P Wisnivesky
Journal:  J Clin Oncol       Date:  2015-08-03       Impact factor: 44.544

6.  Naked cuticle Drosophila 1 expression in histologic subtypes of small adenocarcinoma of the lung.

Authors:  Sangjeong Ahn; Won Hwangbo; Hyunchul Kim; Chul Hwan Kim
Journal:  Korean J Pathol       Date:  2013-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.